Assenagon Asset Management S.A. decreased its position in DaVita Inc. (NYSE:DVA – Free Report) by 63.6% during the 3rd quarter, Holdings Channel reports. The firm owned 4,768 shares of the company’s stock after selling 8,318 shares during the quarter. Assenagon Asset Management S.A.’s holdings in DaVita were worth $451,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Resources Management Corp CT ADV grew its holdings in DaVita by 5,900.0% in the second quarter. Resources Management Corp CT ADV now owns 300 shares of the company’s stock valued at $30,000 after purchasing an additional 295 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in DaVita in the second quarter valued at $33,000. Harbor Investment Advisory LLC acquired a new stake in DaVita in the third quarter valued at $34,000. Parkside Financial Bank & Trust grew its holdings in DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock valued at $35,000 after purchasing an additional 147 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in DaVita in the second quarter valued at $36,000. Institutional investors and hedge funds own 84.69% of the company’s stock.
Analyst Ratings Changes
A number of analysts recently commented on the company. UBS Group decreased their price objective on DaVita from $142.00 to $113.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. TheStreet lowered DaVita from a “b-” rating to a “c” rating in a research note on Monday, October 23rd. Finally, Truist Financial decreased their price objective on DaVita from $115.00 to $104.00 and set a “hold” rating on the stock in a research note on Wednesday, October 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, DaVita presently has a consensus rating of “Moderate Buy” and an average price target of $102.67.
DaVita Stock Performance
NYSE DVA opened at $111.61 on Thursday. The business’s 50-day moving average price is $106.68 and its 200 day moving average price is $98.73. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $116.97. The company has a market capitalization of $10.19 billion, a PE ratio of 17.12, a price-to-earnings-growth ratio of 0.76 and a beta of 1.00. The company has a current ratio of 1.24, a quick ratio of 1.19 and a debt-to-equity ratio of 6.01.
DaVita (NYSE:DVA – Get Free Report) last released its earnings results on Tuesday, November 7th. The company reported $2.85 earnings per share for the quarter, topping the consensus estimate of $1.92 by $0.93. DaVita had a return on equity of 63.38% and a net margin of 5.11%. The firm had revenue of $3.12 billion for the quarter, compared to the consensus estimate of $3.02 billion. During the same period in the prior year, the business posted $1.45 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, research analysts predict that DaVita Inc. will post 8.07 earnings per share for the current year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Five stocks we like better than DaVita
- Energy and Oil Stocks Explained
- What are specialty REITs? How to invest in them
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Miso Robotics stock: Is an IPO coming soon?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Insiders are selling these hot stocks on track for higher prices
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.